Erythromycin thiocyanate is a macrolide antibiotic produced by actinomycetes with a broad antibacterial spectrum. It inhibits RNA-dependent protein synthesis by binding to the bacterial 50S ribosomal subunit and blocking transpeptidation and translocation, without interfering with nucleic acid synthesis. It has also shown antitumor and neuroprotective activities in multiple studies.

Methods: The inhibitory effect of erythromycin thiocyanate on the growth of Plasmodium falciparum was detected in vitro.
Results: Erythromycin thiocyanate inhibited the growth of Plasmodium falciparum, with an IC₅₀ of 58.2 μM and an IC₉₀ of 104.0 μM [1].
Methods: Cells were treated with 10 μM and 100 μM erythromycin thiocyanate for 24 h and 72 h, and its antioxidant and anti-inflammatory effects were examined.
Results: Erythromycin thiocyanate exerted antioxidant and anti-inflammatory effects by significantly inhibiting the accumulation of 4-HNE and 8-OHdG, and reducing the expression of Iba-1 and TNF-α (all p<0.01) [4].

Methods: Mice were intragastrically administered erythromycin thiocyanate (0.1–50 mg/kg for 30–120 consecutive days).
Results: At doses ≥5 mg/kg, it inhibited tumor growth and prolonged the survival time of mice [3].
Methods: Tumor-bearing mice were intragastrically administered erythromycin thiocyanate (5 mg/kg or 50 mg/kg).
Results: The 5 mg/kg dose allowed mice to survive 120 days after inoculation, whereas the 50 mg/kg dose shortened the mean survival time of tumor-bearing mice by 4–5 days [3].
Methods: A single subcutaneous injection (i.h.) of erythromycin thiocyanate (50 mg/kg) was administered to rats with cerebral ischemia-reperfusion injury.
Results: Erythromycin thiocyanate exerted protective effects in this model [4].

DMSO: 80 mg/mL (100.88 mM), Sonication is recommended.